Welcome to our dedicated page for Taysha Gene Therapies news (Ticker: TSHA), a resource for investors and traders seeking the latest updates and insights on Taysha Gene Therapies stock.
Taysha Gene Therapies, Inc. (TSHA) is a clinical-stage biotechnology company pioneering AAV-based therapies for severe genetic disorders of the central nervous system. This page aggregates official news and press releases related to TSHA's innovative pipeline, regulatory progress, and strategic initiatives.
Investors and industry professionals will find timely updates on clinical trial developments, including TSHA-102 for Rett syndrome, regulatory designations like RMAT status, and research collaborations advancing gene therapy science. The curated collection serves as a centralized resource for tracking milestones in TSHA's mission to address unmet needs in monogenic CNS diseases.
Content spans multiple categories including therapy development updates, manufacturing advancements, partnership announcements with academic institutions, and financial disclosures. All materials maintain factual reporting on completed events without speculative commentary.
Bookmark this page for streamlined access to verified information about TSHA's progress in developing transformative genetic medicines. Check regularly for new developments in their clinical programs and scientific innovations.
Taysha Gene Therapies (Nasdaq: TSHA) announced the granting of orphan drug designation by the European Commission for TSHA-120, a gene therapy for giant axonal neuropathy (GAN). Clinical data shows a 10-point improvement in motor function by Year 3 compared to a natural decline of 24 points. Biopsy results indicate active nerve regeneration in patients. With 53 patient-years of safety data, TSHA-120 addresses a global patient population of 5,000 and offers a multi-billion dollar opportunity, as there are currently no approved treatments for GAN.
Taysha Gene Therapies (Nasdaq: TSHA) announced its participation in two upcoming events: the International Rett Syndrome Foundation (IRSF) Rett Syndrome Scientific Symposium and the ASCEND Rett Syndrome National Summit, both in Nashville, Tennessee, from April 26 to 30, 2022. Key presentations will include safety assessments of a miniMECP2 AAV9 vector for gene therapy and insights on caregiver perspectives. Taysha emphasizes its commitment to developing AAV-based gene therapies for monogenic CNS diseases, aiming to innovate treatments for both rare and common conditions.
Taysha Gene Therapies (Nasdaq: TSHA) announced its participation in the Chardan Genetic Medicines and Cell Therapy Manufacturing Summit on April 25, 2022. Key executives, including the CEO, CTO, and CMO, will join a panel discussion at 12:00 pm ET focusing on AAV gene therapy manufacturing standards from registration-targeted trials. Following this, a fireside chat will take place at 1:00 pm ET. Taysha is committed to developing AAV-based gene therapies for central nervous system diseases, aiming to translate research into effective treatments.
Taysha Gene Therapies (TSHA) reported significant changes in its strategic focus, prioritizing programs for giant axonal neuropathy (GAN) and Rett syndrome, affecting 5,000 and 350,000 patients respectively. A workforce reduction of 35% aims to enhance operational efficiency as clinical activities for other programs will be paused. Financial results show a net loss of $174.5 million for 2021 and R&D expenses increased by $100 million. Despite challenges, existing cash and financing are expected to extend the cash runway into Q4 2023.
Taysha Gene Therapies has announced the initiation of clinical development for TSHA-102, a gene therapy for Rett syndrome, following approval of the Clinical Trial Application by Health Canada. TSHA-102, utilizing the novel miRARE platform, aims to regulate transgene expression safely. Promising preclinical results were reported, showing improved survival and function in mouse models and a favorable safety profile in non-human primates. Preliminary clinical data are expected by the end of 2022, marking a significant milestone in treating this severe neurodevelopmental disorder affecting over 350,000 patients globally.
Taysha Gene Therapies (Nasdaq: TSHA) has announced plans to report its financial results for the fourth quarter and full year ending December 31, 2021. A corporate update conference call is scheduled for Thursday, March 31, 2022, at 8:00 AM Eastern Time. The company is focused on developing AAV-based gene therapies for treating monogenic diseases in the central nervous system. Taysha combines expertise in drug development with the UT Southwestern Gene Therapy Program to create a robust pipeline aimed at curing these diseases.
Taysha Gene Therapies (Nasdaq: TSHA) will participate in the Guggenheim Genomic Medicines and Rare Disease Day Conference on April 1, 2022, at 4:00 PM ET, and the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022, at 11:45 AM ET. The events will feature discussions led by key executives including RA Session II, Suyash Prasad, and Kamran Alam. Taysha focuses on developing AAV-based gene therapies aimed at curing monogenic diseases of the CNS.
Taysha Gene Therapies (Nasdaq: TSHA) announced participation in two fireside chats at the Oppenheimer 32nd Annual Virtual Healthcare Conference. The first chat, focusing on AAV-based Gene Therapy, will take place on
Taysha Gene Therapies (TSHA) announced promising clinical safety data for its gene therapy targeted at CLN7 Batten disease, presented at the 18th Annual WORLD Symposium. The trial achieved the highest intrathecal dose ever delivered in humans, demonstrating a favorable safety profile with no adverse immune responses or dorsal root ganglia inflammation. The trial, ongoing at UT Southwestern, aims to establish safety and tolerability, with potential implications for a serious, currently untreated disease affecting approximately 4,000 patients globally.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) has reported promising clinical findings for its gene therapy TSHA-120, aimed at treating giant axonal neuropathy (GAN). The data revealed a clinically significant improvement in MFM32 scores across all therapeutic cohorts after one and three years. Specifically, the high dose cohort showed a 5-point improvement compared to an 8-point decline in natural history by Year 1. Additionally, nerve regeneration was confirmed in biopsies. TSHA-120 demonstrated a favorable safety profile over 53 patient-years.
FAQ
What is the current stock price of Taysha Gene Therapies (TSHA)?
What is the market cap of Taysha Gene Therapies (TSHA)?
